MedTrace Logo

Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment

NCT00644917 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-01-13

Study results available
· View outcomes & findings →

Summary

The product is being tested to see if exposure to light causes toxic reactions on the skin.

Conditions

  • Healthy

Interventions

DRUG

Xenaderm

20mg under Finn chambers

DRUG

Placebo

20mg under Finn chambers

Sponsors & Collaborators

  • Healthpoint

    lead INDUSTRY

Principal Investigators

  • Innes Cargill, PhD · Healthpoint, Ltd.

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-02-29
Completion
2008-02-29

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00644917 on ClinicalTrials.gov